Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Sol-Gel Technologies (NASDAQ: SLGL) will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 11:00 am Eastern Time. CEO Alon Seri-Levy will speak at the event. Investors can access a live audio webcast on the company's website, with a replay available for 30 days. Sol-Gel focuses on developing topical drug products for skin diseases, leveraging its microencapsulation technology. The company's pipeline includes treatments for acne and rosacea, along with other early-stage and preclinical assets.

NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the company will present at the BMO 2020 Prescriptions for Success Healthcare Conference.        

100%; border-collapse:collapse !important;">

Details are as follows:
16%; width:16%; min-width:16%;">Speaker:	84%; width:84%; min-width:84%;">Mr. Alon Seri-Levy, Chief Executive Officer
Date:	June 23, 2020
Time:	11:00 am Eastern Time

A live audio webcast will be available in the Investors/Events & Presentations section of the Sol-Gel Technologies website at http://ir.sol-gel.com/events-and-presentations. The webcast replay will also be available at the same link shortly after the conclusion of the event for 30 days.

About Sol-Gel Technologies

Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.

For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433

Investor Contact:
Lee Stern
Solebury Trout
+1 646 378 2922
lstern@soleburytrout.com

Source: Sol-Gel Technologies Ltd.

FAQ

When will Sol-Gel Technologies present at the BMO 2020 Healthcare Conference?

Sol-Gel Technologies will present on June 23, 2020, at 11:00 am Eastern Time.

Who is speaking at the BMO 2020 Healthcare Conference for Sol-Gel Technologies?

CEO Alon Seri-Levy will be the speaker for Sol-Gel Technologies.

How can I access the Sol-Gel Technologies presentation at the BMO 2020 Conference?

The presentation can be accessed via a live audio webcast on Sol-Gel's website in the Investors/Events & Presentations section.

What are the main products that Sol-Gel Technologies is developing?

Sol-Gel is developing treatments for acne vulgaris, papulopustular rosacea, and other skin diseases using its proprietary technologies.

What is the focus of Sol-Gel Technologies?

Sol-Gel Technologies focuses on identifying, developing, and commercializing branded and generic topical drug products for skin diseases.